← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS › Sulfonylureas
glibornuride
A10BB04
Forms & Strengths
- Tablets: 12.5 mg
- Tablets: 25 mg
Adult Dosing
- Initial dose: 12.5 mg to 25 mg daily taken before breakfast.
- Maintenance dose: 12.5 mg to 75 mg daily, adjusted based on blood glucose levels.
- Maximum daily dose: 75 mg, higher doses rarely provide additional benefit.
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established; use is generally not recommended in children.
Indications
- Type 2 diabetes mellitus when diet, exercise, and weight reduction are insufficient to control hyperglycemia.
Mechanism of Action
- Second-generation sulfonylurea that stimulates insulin secretion from pancreatic beta cells by closing ATP-sensitive potassium channels, reducing membrane potential and opening voltage-gated calcium channels.
Contraindications
- Hypersensitivity to glibornuride or other sulfonylureas/sulfa derivatives
- Type 1 diabetes mellitus
- Diabetic ketoacidosis or diabetic pre-coma/coma
- Severe hepatic impairment
- Severe renal impairment
- Pregnancy and lactation
Adverse Reactions
- Hypoglycemia (most common and significant)
- Gastrointestinal disturbances (nausea, vomiting, heartburn, diarrhea)
- Weight gain
- Transient visual disturbances
- Rarely: hematologic abnormalities (leukopenia, thrombocytopenia, agranulocytosis), cholestatic jaundice, and skin hypersensitivity reactions
Drug Interactions
- Potentiation of hypoglycemic effect with NSAIDs, salicylates, sulfonamides, coumarin derivatives, MAO inhibitors, beta-blockers, and chloramphenicol
- Attenuation of hypoglycemic effect with thiazide diuretics, corticosteroids, oral contraceptives, sympathomimetics, and thyroid hormones
- Potential for acute hypoglycemia or alcohol intolerance (disulfiram-like reaction) with concurrent alcohol consumption
Curated Content: Needs Vetting Before Put to Clinical Use